Financial Performance - The company's revenue for Q1 2021 was ¥68,551,289.98, representing a 62.61% increase compared to ¥42,157,957.36 in the same period last year[8]. - Net profit attributable to shareholders reached ¥22,890,054.71, a significant increase of 778.18% from ¥2,606,541.85 year-on-year[8]. - The net profit after deducting non-recurring gains and losses was ¥22,087,724.13, up 1,030.70% from ¥1,953,454.09 in the previous year[8]. - Basic earnings per share rose to ¥0.0882, reflecting a 521.13% increase from ¥0.0142 in the previous year[8]. - Operating profit surged to ¥27,179,641.55, compared to ¥3,194,503.68 in the prior period, indicating a substantial increase of approximately 751.5%[42]. - Net profit for the current period was ¥23,295,330.69, up from ¥2,805,353.41, reflecting an increase of around 728.5%[42]. Cash Flow - The net cash flow from operating activities was ¥29,993,137.21, an increase of 221.88% compared to ¥9,318,196.24 in the same period last year[8]. - Cash flow from operating activities amounted to ¥64,485,326.05, compared to ¥38,925,031.49 in the previous period, indicating an increase of about 65.7%[48]. - Operating cash inflow for the first quarter was CNY 65,825,411.63, an increase from CNY 43,117,982.61 in the previous period, representing a growth of approximately 52.5%[49]. - Net cash flow from operating activities was CNY 29,993,137.21, significantly higher than CNY 9,318,196.24 in the same period last year, indicating a year-over-year increase of about 221.5%[49]. - The company reported a net cash inflow of CNY 221,981,848.95 for the quarter, compared to a net outflow of CNY 6,255,409.46 in the same quarter last year[50]. Assets and Liabilities - Total assets at the end of the reporting period were ¥961,208,203.55, a 31.66% increase from ¥730,072,786.50 at the end of the previous year[8]. - Current assets rose significantly to CNY 306,126,406.50, compared to CNY 77,414,229.84 at the end of 2020, marking an increase of about 295.5%[31]. - The company's total liabilities amounted to CNY 108,932,515.09, up from CNY 100,591,420.27, indicating a rise of about 3.3%[33]. - Shareholders' equity increased to CNY 852,275,688.46 from CNY 629,481,366.23, showing a growth of approximately 35.4%[35]. - The total liabilities to equity ratio improved to approximately 12.8% from 16.0%, indicating a stronger equity position[33]. Market Development - The company added 111 new customers during the reporting period, contributing to an increase in market share[20]. - Revenue for the reporting period increased by 62.61% year-over-year, reaching 68.55 million, attributed to the low revenue base from the previous year due to the pandemic[17]. - Net profit surged by 730.39% year-over-year, amounting to 22.89 million, as a result of enhanced market development and increased customer orders[17]. Future Strategies and Risks - The company aims to achieve a revenue target of 266.59 million and a net profit target of 70.67 million for the year[19]. - Future strategies include strengthening technological innovation and expanding into new markets, particularly in sterilization services and radiation technology applications[21]. - Risks identified include potential pandemic resurgence, market demand fluctuations, and safety/environmental risks associated with nuclear technology applications[24].

Financial Performance - The company's operating revenue for 2020 was approximately ¥255.96 million, representing a 1.07% increase from ¥253.26 million in 2019[17]. - The net profit attributable to shareholders for 2020 was approximately ¥61.54 million, reflecting a 5.54% increase compared to ¥58.31 million in 2019[17]. - The net cash flow from operating activities for 2020 was approximately ¥140.52 million, which is an 11.61% increase from ¥125.90 million in 2019[17]. - The basic earnings per share for 2020 was ¥0.3108, up 5.53% from ¥0.2945 in 2019[17]. - The total assets at the end of 2020 were approximately ¥730.07 million, a decrease of 3.82% from ¥759.03 million at the end of 2019[17]. - The net assets attributable to shareholders at the end of 2020 were approximately ¥601.18 million, a slight increase of 0.41% from ¥598.74 million at the end of 2019[17]. - The company reported a quarterly revenue of approximately ¥73.97 million in Q4 2020, with a net profit of approximately ¥15.06 million for the same quarter[19]. - The company’s weighted average return on equity for 2020 was 9.78%, slightly up from 9.68% in 2019[17]. - The net profit after deducting non-recurring gains and losses for 2020 was approximately ¥59.64 million, which is a 5.98% increase from ¥56.28 million in 2019[17]. - The company reported a non-recurring gain of CNY 1,897,459.30 in 2020, a decrease from CNY 2,032,790.60 in 2019, reflecting a decline of approximately 6.6% year-over-year[23]. Business Operations - The main business of the company is irradiation technology services, which includes sterilization services for medical products, food, pharmaceuticals, and packaging materials, contributing significantly to revenue and profit[26]. - The company utilizes cobalt-60 to provide gamma-ray irradiation services, which effectively sterilizes medical products without the need for repackaging, thus preventing secondary contamination[27]. - The irradiation sterilization service for food helps in extending shelf life while maintaining nutritional value, covering products such as fresh poultry, frozen foods, and pet food[29]. - The company’s revenue primarily comes from irradiation technology services, benefiting from the growing demand driven by national economic growth and continuous market expansion efforts[37]. - The company operates a regional management model with service centers in seven major cities, ensuring stable and reliable irradiation services[36]. - The company’s profitability is characterized by a scale effect, where fixed costs related to cobalt sources do not change with service volume, leading to increased profit margins as revenue scales up[38]. - The company has established a procurement system based on demand, implementing a budget management system for procurement activities[39]. - The company’s irradiation modification services improve the physical and chemical properties of polymer materials, which are widely used in various industries including aerospace and automotive[34]. - The company operates 11 gamma irradiation facilities and 1 electron accelerator across 7 major cities, with a project in Zhejiang for sterilizing 300,000 cubic meters of medical devices under construction[41]. - The company has established a quality management system compliant with international standards, receiving over 30 second-party audits and maintaining certifications from BSI, TUV, and others[42]. Market and Customer Relations - The company has seen a positive impact on business performance due to increased sterilization demand for medical products related to the pandemic, despite some negative effects from operational disruptions[47]. - The company is expanding its market presence by enhancing customer service, increasing irradiation technology applications, and maintaining long-term relationships with core clients[47]. - The company has developed customized sterilization solutions based on client needs, ensuring service quality through full-process monitoring of irradiation doses[43]. - The company has a sales management system that coordinates market development plans across subsidiaries, focusing on long-term partnerships with key clients[44]. - The company has strengthened resource sharing among regional sites to improve cobalt utilization and enhance bargaining power[48]. - The company is committed to maintaining compliance with regulatory requirements for cobalt source procurement and transportation, ensuring safety and operational efficiency[40]. Research and Development - In 2020, the company initiated 29 new technology research projects, filed 1 invention patent, and 34 utility model patents, along with 3 software copyrights[56]. - The company has maintained a stable core technical team, ensuring no significant changes during the reporting period[57]. - The company has established a comprehensive quality management system in accordance with international standards, ensuring reliable dose measurement and product quality[58]. - The company launched 17 new applications in the field of irradiation technology during the reporting period[95]. - The number of R&D personnel was 115, accounting for 20.35% of the total workforce[96]. Financial Management and Dividend Policy - The company plans to distribute a cash dividend of ¥1.6 per 10 shares to all shareholders, based on a total of 264,001,897 shares[5]. - The cash dividend distributed in 2020 accounted for 100% of the total distributable profit of 43,398,186.88 yuan[125]. - The company has consistently maintained a cash dividend distribution policy over the past three years[126]. - The total cash dividend for 2020 was 42,240,303.52 yuan, which is a significant amount compared to previous years[128]. - The company’s cash dividend policy aligns with its articles of association and dividend management practices[125]. - The company plans to distribute cash dividends amounting to no less than 10% of the distributable profits achieved in each of the next three years following its listing[141]. - Cumulatively, the cash dividends distributed over the three years should not be less than 30% of the average annual distributable profits during that period[141]. - The company emphasizes a stable profit distribution mechanism, prioritizing cash dividends as the main form of profit distribution[142]. - The company will ensure that cash dividends are only distributed when it has positive cumulative undistributed profits and sufficient cash flow[142]. Compliance and Governance - The company has committed to not engaging in any business activities that may directly or indirectly compete with its subsidiary, 中金辐照, ensuring no new similar business entities will be established or acquired[136]. - The company will ensure compliance with all relevant laws and regulations regarding share reduction[135]. - The company will disclose any failure to fulfill commitments promptly, including the specific reasons and actions taken to protect investor rights[148]. - The company will not engage in any form of financial assistance to related parties that could harm shareholder interests[149]. - The company will ensure that all related transactions are conducted according to legal procedures and disclosed in a timely manner[149]. Environmental and Social Responsibility - The company complies with environmental protection regulations, with its subsidiaries meeting national standards for waste disposal[179]. - The company has not conducted any poverty alleviation work during the reporting period and has no subsequent plans[175].